Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

Patients treated with Satraplatin Demonstrated Statistically Significant Improvement in Pain Response and PSA Response Rates

BERLIN, March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation and GPC Biotech AG today announced additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) which were presented today at the 22nd Annual European Association of Urology Congress in Berlin, Germany. The trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) who have failed prior chemotherapy.

"Second-line chemotherapy for patients with hormone-refractory prostate cancer represents a true unmet medical need and the encouraging satraplatin data suggest that for the first time, we may have a treatment option for these patients with advanced disease," said Professor Fred Witjes, Professor of Urology, Academisch Ziekenhuis, Nijmegen, The Netherlands. "In particular, the very impressive pain and PSA response rates seen in the SPARC study, especially considering the fact that all these patients were progressive after hormones and chemotherapy, further suggest satraplatin's active anti-tumor effect in this patient population."

Data presented today from the SPARC study showed that pain response rates for patients treated with satraplatin were statistically significantly superior compared to the pain response rates for those patients in the comparator arm. Pain response rates were 24.2 percent for the satraplatin plus prednisone arm compared with 13.8 percent for the placebo arm (p=0.005).

Pain response was assessed by patients using a weekly present pain intensity (PPI) and analgesic score. The PPI score was defined according to the McGill-Melzack questionnaire with 0 = no pain, 1 = mild pain, 2 = discomforting pain, 3
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:5/4/2015)... 4, 2015 RadiologyAuction will have their first auction ... product demonstrations at the end of the auction on ... Kodak and Fuji Cr,s, Agfa and Sony, printers and ... event. Various imaging equipment will be available at later ... After years of buying and selling imaging equipment, the ...
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... announces that a new market research report ... Byetta (Type 2 Diabetes) – Analysis ... http://www.reportlinker.com/p0657148/Byetta-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Byetta (Type ... 2020 Summary ...
... Reportlinker.com announces that a new market research ... Aesthetic Lasers and Energy Devices - ... http://www.reportlinker.com/p0575304/Aesthetic-Lasers-and-Energy-Devices---Global-Market-Briefing-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Beauty_Salon_and_Services Aesthetic Lasers ... 2017 Summary ...
Cached Medicine Technology:Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 5Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 2Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 4Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 5Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 7Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 8Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 9
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Jones Arena in Charlottesville, VA. McCartney is one ... music business and this beloved performer continues to roll along ... member of two legendary groups: Wings and The Beatles, has ... since 2013 on the “Out There” tour and has continually ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... Mother Hale Learning Center from Hale House. The Mother ... by offering high-quality, affordable Early Childhood Education. Sheltering Arms ... families will continue to be served by the center. ... serves 45 children ages six weeks to five years, ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... In response to the proposed ... Force (USPSTF), Strategic Radiology® (SR®) fully aligns itself ... and Gynecologists (ACOG), the American College Of Surgeons, ... Society (ACS), American College of Radiology (ACR), and ... regular screening mammography for women beginning at age ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5
... to a recent Florida State University study, hospitals can ... IT// for all hospital operations. ,According to ... Manatee Memorial and Lakewood Ranch Medical Centre, have already ... few years. He said that, the hospitals are yet ...
... beyond the youth segments as far as their clientele is concerned. ... in Japan has taken to "Brain Train" concept like a duck ... million of its "Brain Training for Adults" game, which was released ... were not interested in video games ... But we did not ...
... are that is the medicine metformin is taken once daily ... ,In the words of co-author Dr. Bret Berner, "With ... 2000 mg a day. The new formulation, which goes by ... higher doses.” ,Dr. Bret Berner is chief scientific ...
... MIT scientists have developed a technology that uses the ... which function as in very thin lithium-ion batteries.// ... Yet-Ming Chiang have by simply manipulating a few genes ... the viruses grow and self-assemble into a functional electronic ...
... people who escaped from the horrifying attacks on the World ... depression, anxiety and other psychological problems even three years after ... Centers for Disease Control and Prevention said that the people ... breathing problems of a severe nature. "The trauma of being ...
... with the proposal of the Ministry of Health to hike ... ,"A committee has been set up to review fees ... private medical sector. This includes the licensing and renewal of ... of the medical or health establishments as well," said Dr ...
Cached Medicine News:Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products: